
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Scoliosis : An update on treatments for children and adolescents Puzzler : Acute shock during Lent Dermcase : More than "Ugg-ly" feet Streamlining your office with technology






